
On final dash to the clinic, ArsenalBio hauls in $220M for 'modular' cell therapy approach
If ArsenalBio does it right, its first CAR-T candidate — a potential treatment for ovarian cancer — will be in the clinic later this year.
And a group of deep-pocketed investors are betting $220 million that it can.
South San Francisco-based ArsenalBio launched out of the gate in late 2019 amid a wave of activity forming around cell therapy 2.0, with promises of putting together an “arsenal” of technologies that can engineer cells more precisely, in order to strike the perfect balance on efficacy and safety.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,600+ biopharma pros reading Endpoints daily — and it's free.